About this trial
This study aims to compare the Quadro-Iliac Plane Block versus Erector Spinae Plane Block after total hip arthroplasty.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Age ≥ 18 years.
Both sexes.
American Society of Anesthesiology (ASA) physical status I-III.
Undergoing total hip arthroplasty (THA) under spinal anesthesia.
Disqualifiers
History of allergies to local anesthetics.
Opioid dependency.
Body mass index (BMI) > 35 kg/m2.
Cognitive impairment.
Trial design
Parallel
Treatments tested in this trial
Quadro-iliac plane block
Other interventionPatients will receive ipsilateral Quadro-iliac plane block (QIPB) using 20ml of bupivacaine 0.25%.
Erector spinae plane block
Other interventionPatients will receive ipsilateral erector spinae plane block (ESPB) using 20ml of bupivacaine 0.25%.
Treatment groups
Trial outcomes
Primary outcomes
Time to the first rescue analgesia
Time to the first request for the rescue analgesia will be recorded from the end of surgery to first dose of morphine administrated.
Secondary outcomes
Total morphine consumption
Rescue analgesia of morphine will be given as 3 mg bolus if the numeric rating scale (NRS) \> 3 to be repeated after 30 min if pain persists until the NRS \< 4.
Degree of pain
Each patient will be instructed about postoperative pain assessment with the numeric rating scale (NRS). NRS (0 represents "no pain" while 10 represents "the worst pain imaginable"). NRS will be assessed at post-anesthesia care unit (PACU), 2, 4, 6, 8, 12, 18, and 24 h postoperatively.
Quality of recovery
The quality of recovery (QoR-15) score, will be assessed 24 hours postoperatively. This tool consists of 15 questions, each scored on a 10-point scale, yielding a maximum of 150. It encompasses five domains; physical comfort (questions 1-4, 13), emotional state (questions 9, 10, 14, 15), psychological support (questions 6, 7), physical independence (questions 5, 8), and pain (questions 11, 12
Incidence of adverse events
Incidence of adverse events such as bradycardia, hypotension, nausea, vomiting, respiratory depression, pruritus, or any other complication will be recorded.
Sponsors and contacts
Click on the lead sponsor to view all of their trials.